Researchers from Bellvitge University Hospital (HUB) and IDIBELL have participated in a clinical trial that has demonstrated the efficacy of sebetralstat, a new oral treatment for hereditary angioedema attacks (HAE). Published in The New England Journal of Medicine, the results of this study, in which two patients from the HUB have participated, are the first advance in a decade in the on-demand treatment of this disease.

The KONFIDENT trial has shown that this new treatment provides faster symptom relief compared to placebo, with complete resolution of attacks in less time. The drug, which avoids the need for injections, will significantly improve the quality of life for patients with HAE, which affects one in 50,000 people worldwide.

Until now, treatments for acute attacks of HAE required parenteral administration, but sebetralstat, a kallikrein inhibitor, transforms this approach, allowing patients to take pills instead of injectable medications, making it easier to treat attacks early.

According to Dr. Ramon Lleonart, head of the Allergology Service of the HUB and IDIBELL researcher who signs the article, “this treatment in pills leads to a great improvement in quality of life, since currently patients must carry parenteral treatments with the comfort problems that this entails, due to the fact that the attacks are unpredictable and, therefore, it is necessary that they are always prepared for an eventual attack.”

HAE Center of Excellence Worldwide

The Allergology Service of the Bellvitge Hospital, recently accredited as a centre of reference and excellence (ACARE) in hereditary angioedema, offers comprehensive care to patients with a multidisciplinary team made up of professionals from various medical specialities. This accreditation, granted by the GA²LEN and HAEi networks, reaffirms the centre’s commitment to improving the quality of clinical care and research on this disease.